Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines

被引:12
作者
Alam, Md Maqusood [1 ,2 ]
Joh, Eun-Ha [2 ]
Park, Hyerim [1 ,2 ]
Kim, Baek [1 ,3 ]
Kim, Dong-Hyun [1 ,2 ]
Lee, Yong Sup [1 ,2 ]
机构
[1] Kyung Hee Univ, Dept Pharm, Coll Pharm, Seoul 130701, South Korea
[2] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul 130701, South Korea
[3] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA
基金
新加坡国家研究基金会;
关键词
Alkylphosphocholine; Cytotoxicity; Akt phosphorylation; Miltefosine; Perifosine; Edelfosine; ET-18-OCH3; EDELFOSINE; ANTICANCER AGENT; PHASE-II; IN-VIVO; PERIFOSINE; TUMOR; APOPTOSIS; ANALOGS; TARGET; CELLS;
D O I
10.1016/j.bmc.2013.01.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Akt is activated in most human cancers and contributes to cell growth, proliferation and cellular survival pathway. Accordingly, it is an attractive target for anticancer therapy. A series of novel alkylphosphochlines, incorporating cyclopentanecarboxylate in the phospholipid head group with trans and cis orientations, were synthesized and evaluated for their Akt phosphorylation inhibitory activities and cytotoxicities against human cancer cell lines, A549, MCF-7 and KATO III. Among the synthesized compounds, 5a, 5b and 6c exhibited potent inhibitory Akt phosphorylation effects with IC50 value of 3.1, 2.0 and 3.0 mu M, respectively, and their potencies were better than those of three reference compounds miltefosine, perifosine and edelfosine. All the new compounds, except 5d and 6e, displayed more potent growth inhibition against A549 cells than reference compounds. Specifically, compound 5b exhibited most remarkable cytotoxicities on A549 cells as well as MCF-7 and KATO III cells. Importantly, the cytotoxic effects of these compounds correlated with their Akt phosphorylation inhibitory activities. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2018 / 2024
页数:7
相关论文
共 43 条
[1]  
Ahmed I., 1915, CANCER RES, V1997, P57
[2]   Synthesis and biological evaluation of cyclopentane-linked alkyl phosphocholines as potential anticancer agents that act by inhibiting Akt phosphorylation [J].
Alam, Md Maqusood ;
Joh, Eun-Ha ;
Kim, Yuri ;
Oh, Yeon Il ;
Hong, Jongki ;
Kim, Baek ;
Kim, Dong-Hyun ;
Lee, Yong Sup .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 47 :485-492
[3]   Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue [J].
Andresen, TL ;
Jensen, SS ;
Madsen, R ;
Jorgensen, K .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7305-7314
[4]   Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer [J].
Bendell, Johanna C. ;
Nemunaitis, John ;
Vukelja, Sasha J. ;
Hagenstad, Christopher ;
Campos, Luis T. ;
Hermann, Robert C. ;
Sportelli, Peter ;
Gardner, Lesa ;
Richards, Donald A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) :4394-4400
[5]   CLINICAL PHASE-I PILOT-STUDY OF THE ALKYL LYSOPHOSPHOLIPID DERIVATIVE ET-18-OCH3 [J].
BERDEL, WE ;
FINK, U ;
RASTETTER, J .
LIPIDS, 1987, 22 (11) :967-969
[6]   Cytotoxic etherphospholipid analogues [J].
Berkovic, D .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1998, 31 (04) :511-517
[7]   ANALOGS OF ALKYLLYSOPHOSPHOLIPIDS - CHEMISTRY, EFFECTS ON THE MOLECULAR-LEVEL AND THEIR CONSEQUENCES FOR NORMAL AND MALIGNANT-CELLS [J].
BRACHWITZ, H ;
VOLLGRAF, C .
PHARMACOLOGY & THERAPEUTICS, 1995, 66 (01) :39-82
[8]   Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro [J].
Chen, Min-Bin ;
Wu, Xiao-Yang ;
Tao, Guo-Qing ;
Liu, Chao-Ying ;
Chen, Jian ;
Wang, Li-Qiang ;
Lu, Pei-Hua .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (11) :2487-2498
[9]   Two efficient four-step routes to marine toxin tanikolide [J].
Chen, QS ;
Deng, HB ;
Zhao, JR ;
Lu, Y ;
He, MY ;
Zhai, HB .
TETRAHEDRON, 2005, 61 (35) :8390-8393
[10]   The Akt/PKB pathway: molecular target for cancer drug discovery [J].
Cheng, JQ ;
Lindsley, CW ;
Cheng, GZ ;
Yang, H ;
Nicosia, SV .
ONCOGENE, 2005, 24 (50) :7482-7492